Abstract: A transport device includes: an endless first transporter configured to transport a medium; a second transporter facing the first transporter, and configured to transport the medium while nipping the medium between the first transporter and the second transporter; a first support that supports the first transporter; a second support that supports the first support and is movable relative to the first support; and a separator supported by the second support, and configured to separate the medium from the first transporter.

Abstract: Provided are methods of preventing, delaying, mitigating, reducing and/or inhibiting alpha-synuclein aggregates in the brains of a subject at risk of developing or suffering a cognitive disease associated with, caused and/or mediated at least in part by alpha-synuclein aggregates, for example, Parkinson's Disease or Dementia with Lewy Bodies (DLB).

Abstract: A tire abnormality determination system can include: a related information acquisition portion that acquires deterioration-related information that may exert influence on deterioration of a non-pneumatic tire mounted on a vehicle; a first determination processing portion that determines, based on the deterioration-related information, at least one of presence or absence of a sign of an abnormality in the non-pneumatic tire and presence or absence of the abnormality in the non-pneumatic tire; and an output processing portion that outputs a first determination result of the first determination processing portion to a predetermined output destination.

Abstract: A rotary operator includes: a first rotating body rotatable around an imaginary rotation axis; a second rotating body being detachably attached, and being configured to rotate integrally with the first rotating body and also being rotatable around the rotation axis independently of the first rotating body; and a friction adjusting member being covered by the second rotating body as viewed from a side of the second rotating body with respect to the first rotating body and being configured to adjust friction force between the first rotating body and the second rotating body, in which the first rotating body includes: an installation portion to which the friction adjusting member is detachably attached; and a first engagement portion, and the second rotating body includes a second engagement portion engageable with the first engagement portion.

Abstract: The present invention provides a flush toilet apparatus that includes a flush toilet main body, and a flush water tank that is fixed via at least two fixing points and causes flush water to flow into a water inlet of the flush toilet main body, in which the water inlet is provided at a position eccentric to one side with respect to a lengthwise center line of the flush toilet main body, two of fixing points are each disposed on both sides of the discharge port, and are disposed so that a straight line connecting the two fixing points passes through the discharge port in a top view, and the fixing point located on a rear side among the two fixing points is located closer to the lengthwise center line of the flush toilet main body than a center point of the discharge port.

Abstract: A siphon jet flush toilet comprises: a bowl; a rim spout port suppling flush water to the bowl; a discharge trap conduit; a jet spout port spouting flush water toward an inlet of the discharge trap conduit; a reservoir tank including a jet spouting discharge valve and storing flush water; a jet water conduit configured to guide the flush water in the reservoir tank to the jet spout port; and a controller being configured to control a rim spouting in which the flush water is spouted from the rim spout port and a jet spouting in which the flush water is spouted from the jet spout port, wherein the jet spouting discharge valve includes a valve body, the valve body being arranged at a position that is lower than an upper surface of the bowl and higher than a seal water level, and before opening the jet spouting discharge valve, the flush water is supplied to the jet water conduit.

Abstract: A seatback includes a pressure-receiving member and a drive mechanism. The pressure-receiving member includes a first pressure-receiving portion configured to support a lumbar region of an occupant, and a second pressure-receiving portion joined to an upper part of the first pressure-receiving portion and configured to support a back of the occupant in cooperation with the first pressure-receiving portion. The drive mechanism is configured to displace the pressure-receiving member between a support position and a non-support position, which is a position rearward of the support position. The pressure-receiving member is configured, when in the support position, to be bent at a joining portion where the first pressure-receiving portion and the second pressure-receiving portion are joined together to become convex toward a seat front side.

Abstract: The present invention is to provide a preventive or therapeutic agent for a neurodegenerative disease or a cognitive dysfunction, containing a compound represented by a following formula (I) or a pharmacologically acceptable salt thereof as an active ingredient.

Abstract: Provided is a novel compound having rapid and long-lasting therapeutic effects on diseases exhibiting depressive symptoms. Specifically, provided are an agent for prevention and/or treatment of a depressive symptom, consisting of R(?)-ketamine or a pharmacologically acceptable salt thereof, and a pharmaceutical composition for prevention and/or treatment of a depressive symptom, comprising R(?)-ketamine or a pharmacologically acceptable salt thereof in an effective amount for reducing a depressive symptom, and being substantially free of S(+)-ketamine, and a pharmacologically acceptable salt thereof.

Abstract: A terminal receives a download notification of a profile configured in an embedded subscriber identification module from a push server. The terminal accesses the download destination in accordance with the download notification and receives the profile. The terminal configures the profile to the embedded subscriber identification module. In other aspects, a communication system, a method for controlling a terminal, and a method for controlling a communication system are also disclosed.

Abstract: A winding core includes a winding core portion extending in a length direction; and first and second flange portions respectively provided at first and second end portions of the winding core portion in the length direction, and each having a bottom surface, a top surface on a side opposite to the bottom surface, an inner end surface facing the winding core portion side, and an outer end surface on a side opposite to the inner end surface, with a convex step portion on the top surface side of the outer end surface. The winding core portion has an upper surface facing substantially the same direction as a direction in which the top surface faces. A first straight line passing through the top surface and a second straight line passing through the upper surface intersect outside the outer end surface at an angle of from 0.3 degrees to 5 degrees.

Abstract: This preventive or therapeutic agent for inflammatory diseases or bone diseases, and this pharmaceutical composition for preventing or treating inflammatory diseases or bone diseases include, as effective components, a compound represented by formula (1) or a pharmaceutically acceptable salt thereof. [In formula (1), X is a hydrogen atom, a halogen atom, or a C1-C10 alkyl group that may be substituted; R1 is a C1-C10 alkyl group that may be substituted, a C1-C10 alkenyl group that may be substituted, or a C6-C14 aryl group that may be substituted; and one or more hydrogen atoms may be substituted with deuterium atoms.

Abstract: Provided herein are methods of preventing, reducing, ameliorating, mitigating, inhibiting, treating and/or reversing a neurodevelopmental disorder related to prenatal maternal immune activation in an individual in need thereof comprising administering to said individual an agent that increases the level of epoxy-fatty acids wherein said individual experienced maternal immune activation one or more times during gestation. Also provided herein are methods of preventing, reducing, ameliorating, mitigating, inhibiting treating and/or reversing schizophrenia or autism spectrum disorder an individual comprising administering to said individual an agent that increases the level of epoxy-fatty acids.

Abstract: The control unit includes a retrieval target article identification unit configured to identify a retrieval target article from among the articles stored in the storage unit on the basis of retrieval information indicating a retrieval completion state, a reverse sequential operation calculation unit configured to calculate a reverse sequential operation when it is assumed that the retrieval target article is moved to the storage position in the storage unit in a reverse sequence from the retrieval completion state, and a retrieval operation calculation unit configured to calculate a retrieval operation in which the retrieval target article is moved from the storage position in the storage unit and is in the retrieval completion state by reproducing the reverse sequential operation in reverse.

Abstract: This air pump device is provided with: an electric pump unit including a pump mechanism and a motor; a case; and a vibration-proof member. The pump mechanism and the motor are arranged side by side in the axial direction of the motor. The pump mechanism has an inlet and an outlet at an end in the axial direction on the opposite side of the motor. The case has a first wall and a second wall which are located on opposite sides in the axial direction of the motor and which face the electric pump unit. The vibration-proof member is provided with: a first axial vibration-proof unit interposed between the electric pump unit and the first wall; and a second axial vibration-proof unit interposed between the electric pump unit and the second wall. The first axial vibration-proof unit covers the inlet.

Abstract: This invention provides methods for preventing, mitigating, ameliorating and/or controlling psychiatric disorders, including depression, major depression, bipolar disorder, schizophrenia and substance abuse (including addiction and dependence) by administration of an agent that increases epoxy-fatty acids (e.g., an inhibitor of soluble epoxide hydrolase), as sole active agent or in combination with another agent (e.g., an antidepressant, an antipsychotic, an anxiolytic). When co-administered in combination with another agent, one or both agent may be administered at a subtherapeutic dose.

Abstract: The present invention provides a prophylactic or therapeutic agent for neurodevelopmental disorder that comprises a compound represented by formula (I) or a pharmacologically acceptable salt thereof as an active ingredient.

Abstract: Provided is a novel compound having rapid and long-lasting therapeutic effects on diseases exhibiting depressive symptoms. Specifically, provided are an agent for prevention and/or treatment of a depressive symptom, consisting of R(?)-ketamine or a pharmacologically acceptable salt thereof, and a pharmaceutical composition for prevention and/or treatment of a depressive symptom, comprising R(?)-ketamine or a pharmacologically acceptable salt thereof in an effective amount for reducing a depressive symptom, and being substantially free of S(+)-ketamine, and a pharmacologically acceptable salt thereof.

Abstract: A seat device includes a holding member that holds an air tube and is located below a seat cushion. The holding member includes a base wall that defines a holding surface for the air tube, a locking portion that locks air tubes routed along the holding surface on the base wall, and a side wall extending in a routing direction of each of the air tubes.

Abstract: Provided is a novel compound having rapid and long-lasting therapeutic effects on diseases exhibiting depressive symptoms. Specifically, provided are an agent for prevention and/or treatment of a depressive symptom, consisting of R(?)-ketamine or a pharmacologically acceptable salt thereof, and a pharmaceutical composition for prevention and/or treatment of a depressive symptom, comprising R(?)-ketamine or a pharmacologically acceptable salt thereof in an effective amount for reducing a depressive symptom, and being substantially free of S(+)-ketamine, and a pharmacologically acceptable salt thereof.